P9623

Paroxetine hydrochloride hemihydrate

≥98% (HPLC), powder, serotonin reuptake inhibitor

• Sinónimos: Paroxetine HCl, (3S-trans)-3-[(1,3-Benzodioxol-5-yloxy)methyl]-4-(4-fluorophenyl)piperidine hydrochloride hemihydrate
• Fórmula empírica (notación de Hill): C₁₉H₂₀FNO₃ · HCl · .5 H₂O
• Número de CAS: 110429-35-1
• Peso molecular: 374.83
• Número MDL: MFCD03658863
• Código UNSPSC: 12352200
• ID de la sustancia en PubChem: 24278249
• NACRES: NA.77

Propiedades

• product name: Paroxetine hydrochloride hemihydrate, ≥98% (HPLC), powder
• Análisis: ≥98% (HPLC)
• formulario: powder
• condiciones de almacenamiento: desiccated
• color: white
• emisor: GlaxoSmithKline
• cadena SMILES: O.Cl[H].Fc1ccc(cc1)[C@@H]2CCNC[C@H]2COc3ccc4OCOc4c3
• InChI: 1S/C19H20FNO3.ClH.H2O/c20-15-3-1-13(2-4-15)17-7-8-21-10-14(17)11-22-16-5-6-18-19(9-16)24-12-23-18;;/h1-6,9,14,17,21H,7-8,10-12H2;1H;1H2/t14-,17-;;/m0../s1
• Clave InChI: QRQSGFFISBKLMZ-YHOFXEKLSA-N
• Información sobre el gen: human ... SLC6A4(6532)

Descripción

Aplicación

Paroxetine hydrochloride hemihydrate has been used: as an antidepressant to study its effects on neural stem cells (NSCs) from embryonic rat hippocampus in vitro; as a CYP 2D6 inhibitor to study its effects on the in vitro production by human recombinant CYP 2D6 of the phenolic metabolites; as an antidepressant to study its effects on the expression of pituitary adenylate cyclase activating polypeptide (PACAP), its receptors and brain-derived neurotrophic factor (BDNF) in rat primary hippocampal neurons

Acciones bioquímicas o fisiológicas

Paroxetine hydrochloride hemihydrate is one of the most potent and selective of the selective serotonin reuptake inhibitors (SSRI); antidepressant

Paroxetine is a phenylpiperidine derivative. It has the ability to cross placenta. Paroxetine is known to increase the risk of congenital cardiac malformations. It might be useful in hormone replacement therapy for treating vasomotor symptoms during menopause. It is known to ameliorate the effects of panic disorder, obsessive‐compulsive disorder and social phobia.

Características y beneficios

This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Información legal

Sold with the permission of GlaxoSmithKline

Información de seguridad

• Pictogramas: GHS07,GHS09
• Palabra de señalización: Warning
• Frases de peligro: H302,H317,H319,H335,H410
• Consejos de prudencia: P261 - P273 - P280 - P301 + P312 - P302 + P352 - P305 + P351 + P338
• Clasificaciones de peligro: Acute Tox. 4 Oral - Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Sens. 1 - STOT SE 3
• Órganos de actuación: Respiratory system
• Código de clase de almacenamiento: 11 - Combustible Solids
• Clase de riesgo para el agua (WGK): WGK 3
• Punto de inflamabilidad (°F): Not applicable
• Punto de inflamabilidad (°C): Not applicable
• Equipo de protección personal: dust mask type N95 (US), Eyeshields, Gloves